KALA Stock Price History and Quote Analysis: Insights for Investors
Kala Pharmaceuticals, Inc.
Stock Price Today
Kala Pharmaceuticals, Inc. (KALA) stock surged +2.08%, trading at $5.40 on NASDAQ, up from the previous close of $5.29. The stock opened at $5.28, fluctuating between $5.25 and $5.40 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Company Information
| Employees | 43 |
| Beta | -2.124 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Frequently Asked Questions
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) stock price is $5.40 in the last trading session. During the trading session, KALA stock reached the peak price of $5.40 while $5.25 was the lowest point it dropped to. The percentage change in KALA stock occurred in the recent session was 2.08% while the dollar amount for the price change in KALA stock was $0.11.
The NASDAQ listed KALA is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Kala Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Mark T. Iwicki
Chairman & Chief Executive Officer
Ms. Michele LaRussa
Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. Darius Kharabi J.D., M.B.A.
Chief Bus. Officer
Ms. Mary Reumuth C.P.A., CPA
Chief Financial Officer & Treasurer
Ms. Jill S. Steier
Executive Director of Investor Relations & Corporation Communications
Ms. Mary Reumuth CPA, CPA
Chief Financial Officer & Treasurer
Mr. James Patnoe
Senior Vice President of Market Access, Commercial Operations & Pricing
Dr. Kim Brazzell Ph.D.
Head of R&D and Chief Medical Officer
Mr. Eric L. Trachtenberg
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Justin Hanes Ph.D.
Founder & Chair of the Scientific Advisory Board
Mr. Vincent Kosewski
Senior Vice President of Manufacturing & Supply Chain Management
Mr. Todd Bazemore
Pres & Chief Operating Officer
KALA's closing price is 28.27% higher than its 52-week low of $4.21 where as its distance from 52-week high of $10.97 is -50.78%.
Number of KALA employees currently stands at 43.
Official Website of KALA is: https://www.kalarx.com
KALA could be contacted at phone 781 996 5252 and can also be accessed through its website. KALA operates from 1167 Massachusetts Avenue, Arlington, MA 02476, United States.
KALA stock volume for the day was 9.21K shares. The average number of KALA shares traded daily for last 3 months was 23.56K.
The market value of KALA currently stands at $24.88M with its latest stock price at $5.40 and 4.61M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com